Benitec Biopharma Inc. BNTC R2K
Healthcare · Biotechnology · United States
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
READ MORE ›$11.56
-24.74% 1Y
Market & Price
Market Cap
$397.14M
Current Price
$11.56
High / Low (52W)
$16.56 / $10.06
Beta
0.28
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$5.34
Price to Book
2.17
P/S
-
EV/EBITDA
-4.58
Dividend Yield
-
Profitability & Returns
ROCE
-42.71%
ROE
-29.58%
ROA
-19.93%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-0.24
EPS (TTM)
$-0.93
Balance Sheet & Liquidity
Debt/Equity
0.48
Quick Ratio
56.43
Current Ratio
56.82
Debt
$876.00K
Total Assets
$99.59M
Current Assets
$98.52M
Working Capital
$96.72M
Ownership
Promoter Holding
2.70%
Chg in Prom Hold
-
FII / Inst Holding
98.25%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$213.25M
Total Revenue (TTM)
-
EBITDA
$-46.54M
Free Cash Flow
$-7.13M
Operating Cash Flow
$-19.79M
Shares Outstanding
34.35M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-33.33%
Profit 5Y
-36.08%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
No notable strengths flagged.
CONS
- Revenue declined at -33.3% CAGR over 5 years.
- Earnings shrank at -36.1% CAGR over 5 years.
- Trading 30.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BNTC Benitec Biopharma Inc. R2K | 11.56 | - | $397.14M | - | -42.71% | -29.58% | -33.33% | -36.08% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Dec 2019 | Mar 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33.00K | 77.00K | 28.00K | 55.00K | 1.00K | 1.00K | 0 | 25.00K | 48.00K | 0 | 14.00K | 54.00K | 0 | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.34M | 17.18M | 9.80M | 13.38M | 13.58M |
| Operating Income | -1.17M | -2.11M | -2.11M | -2.69M | -3.26M | -3.79M | -4.82M | -4.83M | -3.46M | -4.58M | -5.61M | -4.34M | -5.87M | -6.93M | -4.14M | - | - | -15.34M | -17.18M | -9.80M | -13.38M | -13.58M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.23M | -17.06M | -9.69M | -13.26M | -13.46M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.50M | -16.15M | -8.96M | -11.84M | -11.94M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -1.15M | -2.09M | -2.10M | -2.72M | -3.25M | -3.91M | -5.04M | -4.82M | -3.27M | -5.09M | -5.41M | -4.40M | -5.95M | -6.80M | -4.28M | - | - | -14.50M | -16.15M | -8.96M | -11.84M | -11.94M |
| Diluted EPS | - | - | - | - | - | - | -0.62 | -0.59 | -0.40 | -7.98 | -3.34 | -2.67 | -3.05 | -2.64 | -0.23 | - | -0.26 | -0.38 | - | -0.22 | -0.26 | -0.24 |
| R&D Expense | 423.00K | 599.00K | 805.00K | 774.00K | 1.17M | 2.76M | 2.78M | 3.15M | 2.17M | 2.66M | 3.76M | 3.17M | 4.43M | 5.10M | 2.57M | 3.58M | 5.38M | 6.50M | 2.87M | 3.37M | 5.83M | 6.30M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 12.20M | 102.00K | - | 73.00K | 75.00K | 0 | 0 |
| Cost of Revenue | - | - | 123.00K | 9.00K | 0 | - | - |
| Gross Profit | - | - | -64.00K | 64.00K | 75.00K | - | - |
| Operating Expenses | - | - | - | 17.92M | 19.16M | 22.49M | 41.77M |
| Operating Income | 2.58M | -8.28M | - | -17.85M | -19.08M | -22.49M | -41.77M |
| EBITDA | - | - | - | -17.78M | -18.70M | -22.15M | -41.37M |
| Interest Expense | - | - | 6.00K | 32.00K | 33.00K | - | - |
| Pretax Income | - | - | - | -18.21M | -19.56M | -21.75M | -37.92M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | 2.61M | -8.27M | - | -18.21M | -19.56M | -21.75M | -37.92M |
| Diluted EPS | - | - | - | -37.91 | -14.12 | -1.22 | -1.05 |
| R&D Expense | 4.57M | 3.00M | 7.02M | 11.27M | 12.77M | 15.61M | 18.33M |
Compounded Sales Growth
| 5 Years: | -33.33% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -36.08% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -24.74% |
| 6 Months: | -10.60% |
| 3 Months: | +6.06% |
| 1 Month: | -4.86% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 19.23M | 11.59M | - | 5.97M | 4.46M | 52.21M | 99.59M |
| Current Assets | - | - | - | - | 4.82M | 3.73M | 51.67M | 98.52M |
| Cash & Equivalents | 11.88M | 15.72M | 9.80M | - | 4.06M | 2.48M | 50.87M | 97.74M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 3.00K | 55.00K | 229.00K | 33.00K |
| Total Liabilities | - | 2.64M | 1.35M | - | 3.09M | 4.26M | 4.96M | 2.30M |
| Current Liabilities | - | 2.64M | 1.14M | - | 2.53M | 3.98M | 4.92M | 1.80M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 811.00K | 559.00K | 284.00K | 849.00K |
| Total Equity | 13.84M | 16.59M | 10.24M | - | 2.88M | 202.00K | 47.25M | 97.30M |
| Shares Outstanding | - | - | - | - | 480.69K | 1.65M | 10.09M | 26.25M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 4.79M | -7.54M | - | -15.90M | -18.01M | -19.40M | -23.59M |
| Investing Cash Flow | -400.00K | -94.00K | - | -13.00K | -1.00K | -179.00K | -18.00K |
| Financing Cash Flow | - | 1.77M | - | 0 | 16.02M | 68.03M | 70.48M |
| Capital Expenditure | -404.00K | -95.00K | - | -13.00K | -1.00K | -179.00K | -18.00K |
| Free Cash Flow | 4.39M | -7.63M | - | -15.91M | -18.01M | -19.58M | -23.61M |
| Net Change in Cash | - | - | - | -15.91M | -2.00M | 48.45M | 46.88M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 87.7% | 100.0% | - | - |
| Operating Margin % | 21.2% | -8,118.6% | - | -24,457.5% | -25,441.3% | - | - |
| Net Margin % | 21.4% | -8,111.8% | - | -24,942.5% | -26,082.7% | - | - |
| ROE % | 15.7% | -80.8% | - | -631.8% | -9,684.2% | -46.0% | -39.0% |
| ROCE % | 15.6% | -79.2% | - | -518.9% | -3,926.1% | -47.6% | -42.7% |
Shareholding Pattern
Insiders
2.70%
Institutions
98.25%
Public Float
100.98%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Suvretta Capital Management, LLC | 33.62% | 11.55M | $133.50M |
| 2 | Janus Henderson Group PLC | 8.37% | 2.88M | $33.25M |
| 3 | Franklin Resources, Inc. | 6.92% | 2.38M | $27.49M |
| 4 | Adage Capital Partners GP L.L.C. | 6.17% | 2.12M | $24.51M |
| 5 | RA Capital Management, L.P. | 5.39% | 1.85M | $21.39M |
| 6 | Nantahala Capital Management, LLC | 4.19% | 1.44M | $16.63M |
| 7 | Blackrock Inc. | 3.45% | 1.19M | $13.71M |
| 8 | Vanguard Capital Management LLC | 2.71% | 931.56K | $10.77M |
| 9 | Infinitum Asset Management, LLC | 2.69% | 923.01K | $10.67M |
| 10 | Alyeska Investment Group, L.p. | 2.18% | 750.00K | $8.67M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BNTC
No recent headlines available.